The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 14, 2020

Filed:

Feb. 13, 2018
Applicant:

Tricol Biomedical, Inc., Portland, OR (US);

Inventors:

Barbara McGrath, Portland, OR (US);

Simon McCarthy, Portland, OR (US);

Sam Kuhn, Portland, OR (US);

Alysha Wold, Portland, OR (US);

Michael Stolten, New Orleans, LA (US);

Amanda Bennett, New Orleans, LA (US);

Assignee:

Tricol Biomedical, Inc., Portland, OR (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61L 27/26 (2006.01); C08L 89/06 (2006.01); C08L 5/08 (2006.01); G01N 33/50 (2006.01); A61L 27/58 (2006.01); A61L 27/20 (2006.01); C08B 37/08 (2006.01); A61K 47/36 (2006.01); A61K 9/00 (2006.01); A61K 49/00 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61L 27/58 (2013.01); A61K 9/0024 (2013.01); A61K 47/36 (2013.01); A61K 49/0008 (2013.01); A61L 27/20 (2013.01); A61L 27/26 (2013.01); C08B 37/003 (2013.01); C08L 5/08 (2013.01); C08L 89/06 (2013.01); G01N 33/5014 (2013.01); G01N 33/6869 (2013.01); A61L 2400/04 (2013.01); C08L 2201/06 (2013.01); G01N 2333/545 (2013.01); G01N 2400/28 (2013.01);
Abstract

The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.


Find Patent Forward Citations

Loading…